Sarepta Therapeutics | SRPT - Loan Capital


Sarepta Therapeutics reported $838.16M in Loan Capital for its fiscal quarter ending in March of 2026.





Loan Capital Change Date
Acadia Pharmaceuticals USD 0 0 Mar/2025
Agios Pharmaceuticals USD 1.06M 0 Sep/2022
Alnylam Pharmaceuticals USD 2.48B 931K Mar/2026
Amgen USD 51.89B 1.88B Mar/2026
BioCryst Pharmaceuticals USD 395.2M 33.48M Mar/2026
Biogen USD 6.29B 1.7M Mar/2026
BioMarin Pharmaceutical USD 1.43B 833.11M Mar/2026
Capricor Therapeutics USD 3.38M 0 Mar/2025
Daiichi Sankyo JPY 300.15B 199.41B Dec/2025
Eli Lilly USD 39.37B 1.5B Mar/2026
Esperion Therapeutics USD 457.65M 9.5M Dec/2025
Gilead Sciences USD 20.86B 1.27B Mar/2026
Incyte USD 29.41M 785K Mar/2026
Insmed USD 542.22M 1.25M Mar/2026
Ionis Pharmaceuticals USD 1.91B 9M Mar/2026
Moderna USD 603M 7M Mar/2026
Nektar Therapeutics USD 63.16M 44.35M Dec/2025
Neurocrine Biosciences USD 169.5M 500K Mar/2023
Novavax USD 246.3M 200K Dec/2025
Pfizer USD 60.57B 1.08B Mar/2026
PTC Therapeutics USD 286.94M 1.74B Mar/2026
Regeneron Pharmaceuticals USD 1.99B 719.7M Mar/2026
Roche Holding CHF 27.43B 966M Dec/2025
Sangamo BioSciences USD 0 0 Jun/2022
Sanofi EUR 13.84B 1.88B Mar/2026
Sarepta Therapeutics USD 838.16M 9.19M Mar/2026
Tectonic Therapeutic USD 43K 57K Dec/2025
Ultragenyx Pharmaceutical USD 1.13B 19M Mar/2026
Vertex Pharmaceuticals USD 106.7M 4.7M Dec/2025